Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

A Preliminary Study for the Rating of Pharmacological Effect with Aberrant Behavior Checklist in Children with Autistic Disorder

자폐장애 아동의 약물효과 평정을 위한 이상행동 체크리스트 예비연구

  • Moon, Duk-Soo (Department of Psychiatry, Kyungpook National University School of Medicine) ;
  • Chung, Un-Sun (Department of Psychiatry, Kyungpook National University School of Medicine) ;
  • Jung, Sung Hoon (Department of Psychiatry, Kyungpook National University School of Medicine) ;
  • Cho, Ah Rang (Department of Psychiatry, Kyung Hee University School of Medicine) ;
  • Bahn, Geon Ho (Department of Psychiatry, Kyung Hee University School of Medicine)
  • 문덕수 (경북대학교 의학전문대학원 정신건강의학교실) ;
  • 정운선 (경북대학교 의학전문대학원 정신건강의학교실) ;
  • 정성훈 (경북대학교 의학전문대학원 정신건강의학교실) ;
  • 조아랑 (경희대학교 의학전문대학원 정신건강의학교실) ;
  • 반건호 (경희대학교 의학전문대학원 정신건강의학교실)
  • Received : 2013.07.30
  • Accepted : 2013.09.06
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : We assessed the availability of Aberrant Behavior Checklist (ABC) for the evaluation of the pharmacological effect in autistic disorder. Methods : A retrospective review of the medical records of 27 children with autistic disorder, who visited the department of child and adolescent psychiatry of Kyungpook National University Hospital, from October 2011 to February 2013, was conducted. After treatment with risperidone, changes in the severity and improvement of symptoms were measured using ABC at the baseline, 2nd visit and 3rd visit, respectively. Results : The mean daily dose of risperidone increased from $0.66{\pm}0.27mg$ (baseline, initial dose) to $1.02{\pm}0.50mg$, 2nd visit, and $1.19{\pm}0.50mg$, 3rd visit. According to ABC, irritability, lethargy, hyperactivity, and inappropriate speech subscale scores decreased significantly from the baseline to 2nd visit. Irritability and Hyperactivity subscale scores decreased significantly from the 2nd to 3rd visit. All subscales and total scores of ABC decreased significantly from the baseline to 3rd visit. Conclusion : The results of this study suggest that ABC can be used as an efficient tool to measure the symptoms of autistic disorder and to evaluate the medication effect on continuous treatment.

Keywords

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington DC: American Psychiatric Press;2000. p.69-84.
  2. Hillman JL, Neubronder J, Snyder SJ. Childhood Autism. New York: Taylor & Francis Group;2007. p.49.
  3. Volkmar F, Cook EH Jr, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999;38(12 Suppl):32S-54S. https://doi.org/10.1016/S0890-8567(99)80003-3
  4. Scahill L, Martin A. Psychopharmacology. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders. Hoboken: Wiley;2005. p.1102-1122.
  5. Nazeer A, Ghaziuddin M. Autism spectrum disorders: clinical features and diagnosis. Pediatr Clin North Am 2012;59:19-25, ix. https://doi.org/10.1016/j.pcl.2011.10.007
  6. Cho IH, Yoo HK, Son JW, Yoo HJ, Koo YJ, Chung US, et al. The Korean practice parameter for the treatment of pervasive developmental disorders: pharmacological treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:109-116.
  7. Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 2012;129:e771-e784. https://doi.org/10.1542/peds.2011-2158
  8. Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 2008;4:723-730.
  9. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-e641. https://doi.org/10.1542/peds.2003-0264-F
  10. Myers SM, Johnson CP; American Academy of Pediatrics Council on Children With Disabilities. Management of children with autism spectrum disorders. Pediatrics 2007;120:1162-1182. https://doi.org/10.1542/peds.2007-2362
  11. Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2007;37:367-373. https://doi.org/10.1007/s10803-006-0234-7
  12. Karabekiroglu K, Aman MG. Validity of the aberrant behavior checklist in a clinical sample of toddlers. Child Psychiatry Hum Dev 2009;40:99-110. https://doi.org/10.1007/s10578-008-0108-7
  13. Glascoe FP. Early detection of developmental and behavioral problems. Pediatr Rev 2000;21:272-279; quiz 280. https://doi.org/10.1542/pir.21-8-272
  14. Aman MG, Singh NN, Stewart AW, Field CJ. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic 1985; 89:492-502.
  15. Scahill L, Hallett V, Aman MG, McDougle CJ, Eugene Arnold L, et al. Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. J Autism Dev Disord 2013;43:739-746. https://doi.org/10.1007/s10803-012-1689-3
  16. Aman MG, Singh NN, Turbott SH. Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. Am J Ment Defic 1987;92:237-240.
  17. Yoo HJ, Cho IH, Koo YJ, Yoo HI, Son JW, Chung US, et al. The Korean practice parameter for the treatment of pervasive developmental disorders: diagnosis and assessment. J Korean Acad Child Adolesc Psychiatry 2007;18:97-108.
  18. King BH. Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. J Autism Dev Disord 2000;30:439-445. https://doi.org/10.1023/A:1005555624566
  19. Freund LS, Reiss AL. Rating problem behaviors in outpatients with mental retardation: use of the Aberrant Behavior Checklist. Res Dev Disabil 1991;12:435-451. https://doi.org/10.1016/0891-4222(91)90037-S
  20. Marshburn EC, Aman MG. Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation. J Autism Dev Disord 1992;22:357-373. https://doi.org/10.1007/BF01048240
  21. Brinkley J, Nations L, Abramson RK, Hall A, Wright HH, Gabriels R, et al. Factor analysis of the aberrant behavior checklist in individuals with autism spectrum disorders. J Autism Dev Disord 2007;37: 1949-1959. https://doi.org/10.1007/s10803-006-0327-3
  22. Hollander E, Phillips A, King BH, Guthrie D, Aman MG, Law P, et al. Impact of recent findings on study design of future autism clinical trials. CNS Spectr 2004;9:49-56. https://doi.org/10.1017/S109285290000835X
  23. Chavez B, Chavez-Brown M, Sopko MA Jr, Rey JA. Atypical antipsychotics in children with pervasive developmental disorders. Paediatr Drugs 2007;9:249-266. https://doi.org/10.2165/00148581-200709040-00006
  24. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321. https://doi.org/10.1056/NEJMoa013171
  25. Dean AJ, Wragg J, Draper J, McDermott BM. Predictors of medication adherence in children receiving psychotropic medication. J Paediatr Child Health 2011;47:350-355. https://doi.org/10.1111/j.1440-1754.2010.01985.x
  26. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55 Suppl:13-17.

Cited by

  1. Aripiprazole for Irritability in Asian Children and Adolescents with Autistic Disorder: A 12-Week, Multinational, Multicenter, Prospective Open-Label Study vol.28, pp.6, 2018, https://doi.org/10.1089/cap.2017.0152